pdufa.bio
HomeDecisions › GSK 2026-03-13

GSK FDA decision — Mar 13, 2026

✓ APPROVED

GSK plc American Depositary Shares (Each — Arexvy · Lower respiratory tract disease (LRTD) caused by R.

Run-up into the decision (T-120 → T+5)

PDUFA 3/13/26$61.18$39.529/26/25
Daily close, T-120 (9/26/25) through T+5. Run-up high $61.18 on 2/18/26, low $39.52 on 10/2/25 (T-120 to T-1). FDA decision 3/13/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-13
OutcomeApproved
Drug / candidateArexvy
CompanyGSK plc American Depositary Shares (Each
120-day run-up (T-120→T-1)+33.5%